Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share
-
Shares outstanding
-
266,212,950
-
Total 13F shares
-
649,313
-
Share change
-
-536,767
-
Total reported value
-
$1,292,444
-
Price per share
-
$1.99
-
Number of holders
-
6
-
Value change
-
-$853,157
-
Number of buys
-
3
-
Number of sells
-
3
Institutional Holders of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) as of Q4 2025
As of 31 Dec 2025,
Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) was held by
6 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
649,313 shares.
The largest 6 holders included
Hennion & Walsh Asset Management, Inc., SG Americas Securities, LLC, Rathbones Group PLC, Avanza Fonder AB, GAMMA Investing LLC, and Byrne Asset Management LLC.
This page lists
6
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.